Cyclo Therapeutics, Inc. (CYTH)
NASDAQ: CYTH · Real-Time Price · USD
0.630
+0.010 (1.61%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cyclo Therapeutics Revenue
Cyclo Therapeutics had revenue of $233.77K in the quarter ending September 30, 2024, a decrease of -52.82%. This brings the company's revenue in the last twelve months to $870.73K, down -8.52% year-over-year. In the year 2023, Cyclo Therapeutics had annual revenue of $1.08M, down -21.76%.
Revenue (ttm)
$870.73K
Revenue Growth
-8.52%
P/S Ratio
19.56
Revenue / Employee
$108,841
Employees
8
Market Cap
18.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08M | -299.36K | -21.76% |
Dec 31, 2022 | 1.38M | -210.00K | -13.24% |
Dec 31, 2021 | 1.59M | 682.38K | 75.54% |
Dec 31, 2020 | 903.38K | -103.82K | -10.31% |
Dec 31, 2019 | 1.01M | -4.28K | -0.42% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCYTH News
- 1 day ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders - PRNewsWire
- 4 weeks ago - Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio - GlobeNewsWire
- 5 weeks ago - Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - Business Wire
- 4 months ago - CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH - Business Wire
- 4 months ago - Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries - Business Wire
- 4 months ago - Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement - Business Wire
- 4 months ago - Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire